logo
Share SHARE
FONT-SIZE Plus   Neg

Active Biotech, Ipsen Present OS Data From Tasquinimod Phase II Study In CRPC

Active Biotech (ATVBF.PK) and Ipsen presented overall survival, or OS, data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer, or CRPC.

The intention-to-treat analysis showed median overall survival times of 33.4 vs. 30.4 months in favor of tasquinimod, longer than previously reported in this metastatic prostate cancer population. A stronger trend for survival benefit is observed in patients with bone metastases. This phase II clinical trial was designed to test the safety and efficacy of tasquinimod.

Noteworthy, 41 patients crossed-over from placebo to tasquinimod. Besides, there were imbalances in baseline prognostic factor in favor of the placebo arm. These were addressed with a multivariate analysis of known CRPC prognostic factors. It showed a statistically significant OS advantage for tasquinimod treated patients with a hazard ratio of 0.64, a decrease of around 40% in the instantaneous risk of event (death), accompanied by improvement in progression-free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Drug major Johnson & Johnson Tuesday said it expects higher earnings and sales for its fiscal 2017, which are below market estimates. The company also reported solid fourth-quarter results, with adjusted earnings above market estimates, while sales missed their view, despite a growth. In pre-market activity on the NYSE, Johnson & Johnson shares were losing 1.68 percent. Verizon Communications Inc. (VZ) reported fourth-quarter adjusted earnings per share of $0.86 compared to $0.89, prior year. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $0.89 for the quarter. Analysts' estimates typically exclude special items.... German business software maker SAP AG on Tuesday raised its forecast for fiscal 2017 and 2020, after reporting higher profit and revenues in its fourth quarter. For fiscal 2017, SAP now expects non-IFRS operating profit in a range of 6.8 billion euros to 7.0 billion euros at constant currencies, compared to 6.63 billion euros in 2016.
comments powered by Disqus
Follow RTT